Relapsed or Refractory Acute Myeloid Leukemia

Oncology·MeSH: Leukemia

11 drugs in development·9 companies·1 clinical trial

Drug Pipeline by Phase

Approved(2)

Drug	Company
komzifti	Kura Oncology, Inc. (KURA)
Revuforj	Syndax Pharmaceuticals Inc (SNDX)

Phase 1(7)

Drug	Company
ACLX-002	Arcellx, Inc. (ACLX)
ADCLEC.syn1 CAR T cells	Merus N.V. (MRUS)
CB-012	Caribou Biosciences, Inc. (CRBU)
nc525	NextCure, Inc. (NXTC)
sgr-2921	Schrodinger, Inc. (SDGR)
Tazemetostat	Merus N.V. (MRUS)
ZN-d5	Zentalis Pharmaceuticals, Inc. (ZNTL)

Preclinical(1)

Drug	Company
ACLX-004	Arcellx, Inc. (ACLX)

Phase 1/Phase 2(1)

Drug	Company
nkx101	Nkarta, Inc. (NKTX)

BioSniper tracks 11 drugs in development for Relapsed or Refractory Acute Myeloid Leukemia across 9 companies.

There are 1 clinical trial targeting Relapsed or Refractory Acute Myeloid Leukemia tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.